Cargando…
Combined-modality therapy for pulmonary alveolar proteinosis in a remote setting: a case report
BACKGROUND: Pulmonary alveolar proteinosis (PAP) is a rare lung disease characterized by accumulation of phospholipoproteinaceous material in the alveoli. The presentation is nonspecific but typically includes dyspnea; the spectrum of disease includes rapidly progressive hypoxic respiratory failure....
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6417025/ https://www.ncbi.nlm.nih.gov/pubmed/30866900 http://dx.doi.org/10.1186/s12890-019-0822-x |
_version_ | 1783403481032294400 |
---|---|
author | Boyce, Dacia S. K. Lee, John W. Shah, Phalgoon Freeman, Judy H. Aboudara, Matthew C. Hostler, David C. |
author_facet | Boyce, Dacia S. K. Lee, John W. Shah, Phalgoon Freeman, Judy H. Aboudara, Matthew C. Hostler, David C. |
author_sort | Boyce, Dacia S. K. |
collection | PubMed |
description | BACKGROUND: Pulmonary alveolar proteinosis (PAP) is a rare lung disease characterized by accumulation of phospholipoproteinaceous material in the alveoli. The presentation is nonspecific but typically includes dyspnea; the spectrum of disease includes rapidly progressive hypoxic respiratory failure. Whole lung lavage (WLL) is the treatment of choice in symptomatic PAP, but transient worsening of oxygenation sometimes requires salvage modalities of support such as extracorporeal membrane oxygenation (ECMO). Granulocyte macrophage colony-stimulating factor (GM-CSF) plays a role in the pathophysiology of PAP. We highlight a case of severe PAP treated with exogenous GM-CSF and sequential lobar lavage due to the unavailability of salvage methods of oxygenation. CASE PRESENTATION: A 36 year old female was admitted with fevers, chills, and progressive dyspnea. On presentation she was tachypneic, tachycardic, and hypoxemic; labs revealed leukocytosis and lactic acidosis. Chest CT identified diffuse ground glass opacities in a ‘crazy-paving’ pattern. Following intubation due to impending respiratory failure, bronchoscopy with bronchoalveolar lavage was performed. The lavage return stained positive with Periodic Acid Schiff, confirming the diagnosis of PAP. Continued deterioration necessitated treatment; however, at this geographically remote center without ECMO services WLL was judged to carry significant risk. Nebulized GM-CSF was administered without significant improvement. Subcutaneous GM-CSF was administered and isolated subsegmental lavages of the bilateral upper lobes were performed, with rapid improvement in oxygenation. Additional sequential lobar lavage and continued GM-CSF therapy as an outpatient resulted in complete resolution of oxygen requirement and return to normal pulmonary physiology. CONCLUSIONS: The autoimmune form of PAP is the most common, indicating that therapy with GM-CSF may play an important role for many patients. Treatment with WLL may be impractical in some clinical settings due to the expertise and salvage modalities required. Sequential lobar lavage requires less specialized expertise and may incur less risk of refractory hypoxemia. We posit that this combined-modality therapy is ideally suited to geographically-remote centers such as our own. |
format | Online Article Text |
id | pubmed-6417025 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-64170252019-03-25 Combined-modality therapy for pulmonary alveolar proteinosis in a remote setting: a case report Boyce, Dacia S. K. Lee, John W. Shah, Phalgoon Freeman, Judy H. Aboudara, Matthew C. Hostler, David C. BMC Pulm Med Case Report BACKGROUND: Pulmonary alveolar proteinosis (PAP) is a rare lung disease characterized by accumulation of phospholipoproteinaceous material in the alveoli. The presentation is nonspecific but typically includes dyspnea; the spectrum of disease includes rapidly progressive hypoxic respiratory failure. Whole lung lavage (WLL) is the treatment of choice in symptomatic PAP, but transient worsening of oxygenation sometimes requires salvage modalities of support such as extracorporeal membrane oxygenation (ECMO). Granulocyte macrophage colony-stimulating factor (GM-CSF) plays a role in the pathophysiology of PAP. We highlight a case of severe PAP treated with exogenous GM-CSF and sequential lobar lavage due to the unavailability of salvage methods of oxygenation. CASE PRESENTATION: A 36 year old female was admitted with fevers, chills, and progressive dyspnea. On presentation she was tachypneic, tachycardic, and hypoxemic; labs revealed leukocytosis and lactic acidosis. Chest CT identified diffuse ground glass opacities in a ‘crazy-paving’ pattern. Following intubation due to impending respiratory failure, bronchoscopy with bronchoalveolar lavage was performed. The lavage return stained positive with Periodic Acid Schiff, confirming the diagnosis of PAP. Continued deterioration necessitated treatment; however, at this geographically remote center without ECMO services WLL was judged to carry significant risk. Nebulized GM-CSF was administered without significant improvement. Subcutaneous GM-CSF was administered and isolated subsegmental lavages of the bilateral upper lobes were performed, with rapid improvement in oxygenation. Additional sequential lobar lavage and continued GM-CSF therapy as an outpatient resulted in complete resolution of oxygen requirement and return to normal pulmonary physiology. CONCLUSIONS: The autoimmune form of PAP is the most common, indicating that therapy with GM-CSF may play an important role for many patients. Treatment with WLL may be impractical in some clinical settings due to the expertise and salvage modalities required. Sequential lobar lavage requires less specialized expertise and may incur less risk of refractory hypoxemia. We posit that this combined-modality therapy is ideally suited to geographically-remote centers such as our own. BioMed Central 2019-03-12 /pmc/articles/PMC6417025/ /pubmed/30866900 http://dx.doi.org/10.1186/s12890-019-0822-x Text en © The Author(s). 2019 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Case Report Boyce, Dacia S. K. Lee, John W. Shah, Phalgoon Freeman, Judy H. Aboudara, Matthew C. Hostler, David C. Combined-modality therapy for pulmonary alveolar proteinosis in a remote setting: a case report |
title | Combined-modality therapy for pulmonary alveolar proteinosis in a remote setting: a case report |
title_full | Combined-modality therapy for pulmonary alveolar proteinosis in a remote setting: a case report |
title_fullStr | Combined-modality therapy for pulmonary alveolar proteinosis in a remote setting: a case report |
title_full_unstemmed | Combined-modality therapy for pulmonary alveolar proteinosis in a remote setting: a case report |
title_short | Combined-modality therapy for pulmonary alveolar proteinosis in a remote setting: a case report |
title_sort | combined-modality therapy for pulmonary alveolar proteinosis in a remote setting: a case report |
topic | Case Report |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6417025/ https://www.ncbi.nlm.nih.gov/pubmed/30866900 http://dx.doi.org/10.1186/s12890-019-0822-x |
work_keys_str_mv | AT boycedaciask combinedmodalitytherapyforpulmonaryalveolarproteinosisinaremotesettingacasereport AT leejohnw combinedmodalitytherapyforpulmonaryalveolarproteinosisinaremotesettingacasereport AT shahphalgoon combinedmodalitytherapyforpulmonaryalveolarproteinosisinaremotesettingacasereport AT freemanjudyh combinedmodalitytherapyforpulmonaryalveolarproteinosisinaremotesettingacasereport AT aboudaramatthewc combinedmodalitytherapyforpulmonaryalveolarproteinosisinaremotesettingacasereport AT hostlerdavidc combinedmodalitytherapyforpulmonaryalveolarproteinosisinaremotesettingacasereport |